Epidarex leads £4.3m series-A for Mironid

The company is looking to use the fresh capital to support its internal research and pre-clinical development programmes, as well as increase headcount.

Existing backer Scottish Enterprise participated in the funding round. It currently manages one co-investment vehicle, Scottish Coinvestment Fund, as well as Scottish Venture Fund.

Previous funding
The company raised a £500,000 seed round from Scottish Enterprise in 2015 to support its spinout from the University of Strathclyde.

Company
Mironid develops a cell-signalling directed drug, focusing on degenerative kidney diseases, as well as major inflammatory diseases and cancer.

The company was spun out from the University of Strathclyde in 2015. Based in Glasgow, it employs seven people.

People
Epidarex Capital – Sinclair Dunlop (managing partner).
Mironid – Miles Houslay (co-founder, chief scientific officer); Paul Rodgers (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• UK / Ireland
• Scottish Enterprise
• United Kingdom
• Venture